Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07373743 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Mar 2026 to May 2026v2 Show 4 more changesShow less
    • Primary and study completion dates: Jan 2027 to Mar 2027
    • Eligibility criteria expanded, about 17 words
    • Study description revised
    • Study arms: 3 to 4
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn how people's different genetic makeups affects how their bodies convert the FDA approved drug ARAKODA (tafenoquine) to its active form. Tafenoquine is a drug that is taken to prevent malaria for people traveling to areas where there is malaria. This trial will be in healthy participants age 18-65.
Trial Details
NCT Number NCT07373743
Lead Sponsor State University of New York - Upstate Medical University
Conditions
(from sponsor)		 Pharmacokinetic in Normal Population
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov